Gilead Entered into an Agreement with Everest to Develop and Commercialize Trodelvy (sacituzumab govitecan) in Asia Territories
- Everest to receive ~$455M incl. $280M up front and ~$175M upon achievement of regulatory & commercial milestones. The transaction is expected to close in 2022
- Gilead to get exclusive rights to develop & commercialize Trodelvy in Greater China, South Korea, Singapore, Indonesia, Philippines, Vietnam, Thailand, Malaysia & Mongolia. The collaboration helps to expand the product portfolio & internal drug discovery efforts for Trodelvy
- Under the 2019 agreement with Immunomedics, Everest got an exclusive license for Trodelvy in Greater China & other countries (Ex–Japan). Trodelvy was approved in China mainland & Singapore for m-TNBC. Everest has submitted the NDA of Trodelvy for m-TNBC with regulatory bodies in South Korea, Taiwan & Hong Kong
Ref: Gilead | Image: Gilead
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.